Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q6)Sep 30, 2025 | (FY)Mar 31, 2025 | (Q6)Sep 30, 2024 | (FY)Mar 31, 2024 | (Q6)Sep 30, 2023 | (FY)Mar 31, 2023 | (Q6)Sep 30, 2022 | (FY)Mar 31, 2022 | (Q6)Sep 30, 2021 | (FY)Mar 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 1.20%973.35M | -19.93%1.92B | -24.41%961.81M | 12.64%2.4B | 26.15%1.27B | 5.47%2.13B | 0.98%1.01B | -11.21%2.02B | 1.81%998.85M | -22.54%2.28B |
| Operating income | 1.20%973.35M | -19.93%1.92B | -24.41%961.81M | 12.64%2.4B | 26.15%1.27B | 5.47%2.13B | 0.98%1.01B | -11.21%2.02B | 1.81%998.85M | -22.54%2.28B |
| Cost of sales | 3.13%-518.92M | 18.40%-1.06B | 24.13%-535.71M | -14.77%-1.3B | -32.38%-706.13M | -5.72%-1.13B | 2.66%-533.42M | 17.41%-1.07B | 8.84%-548.02M | 23.79%-1.3B |
| Operating expenses | 3.13%-518.92M | 18.40%-1.06B | 24.13%-535.71M | -14.77%-1.3B | -32.38%-706.13M | -5.72%-1.13B | 2.66%-533.42M | 17.41%-1.07B | 8.84%-548.02M | 23.79%-1.3B |
| Gross profit | 6.65%454.43M | -21.75%859.1M | -24.75%426.1M | 10.22%1.1B | 19.16%566.24M | 5.18%996.11M | 5.41%475.2M | -2.96%947.04M | 18.67%450.83M | -20.81%975.93M |
| Selling expenses | 3.37%-205.17M | 21.16%-451.63M | 18.75%-212.33M | -15.56%-572.86M | -25.95%-261.32M | 1.66%-495.72M | -4.32%-207.49M | -68.35%-504.11M | 12.15%-198.9M | 81.94%-299.44M |
| Administrative expenses | -32.61%-78.68M | -8.35%-163.08M | 12.62%-59.33M | -12.68%-150.51M | -8.63%-67.91M | 10.91%-133.57M | 9.22%-62.51M | 3.58%-149.93M | -19.10%-68.86M | 37.42%-155.5M |
| Special items of operating profit | -148.67%-2.96M | -49.11%24.11M | -68.77%6.09M | 213.53%47.38M | 366.33%19.5M | -129.61%-41.73M | 60.06%-7.32M | -140.62%-18.18M | -133.05%-18.33M | -96.83%44.75M |
| Operating profit | 4.42%167.62M | -36.36%268.49M | -37.42%160.52M | 29.78%421.92M | 29.63%256.51M | 18.29%325.09M | 20.11%197.88M | -51.42%274.82M | 9.01%164.74M | -23.34%565.73M |
| Financing cost | 44.59%-12.62M | 40.31%-39.72M | 34.55%-22.78M | -31.21%-66.54M | -79.37%-34.8M | -87.10%-50.72M | -46.83%-19.4M | 16.13%-27.11M | 25.76%-13.22M | 23.51%-32.32M |
| Earning before tax | 12.53%155M | -35.63%228.77M | -37.87%137.74M | 29.52%355.37M | 24.22%221.71M | 10.76%274.38M | 17.78%178.48M | -53.56%247.72M | 13.65%151.53M | -23.33%533.41M |
| Tax | 19.34%-4.96M | -567.78%-30.76M | -210.34%-6.15M | 78.81%-4.61M | 91.44%-1.98M | 53.53%-21.74M | -42.69%-23.16M | 34.66%-46.78M | -14,215.65%-16.23M | -43.52%-71.59M |
| After-tax profit from continuing operations | 14.02%150.03M | -43.55%198.01M | -40.11%131.59M | 38.84%350.77M | 41.47%219.72M | 25.73%252.64M | 14.80%155.31M | -56.49%200.94M | 1.39%135.3M | -28.49%461.82M |
| Earning after tax | 14.02%150.03M | -43.55%198.01M | -40.11%131.59M | 38.84%350.77M | 41.47%219.72M | 25.73%252.64M | 14.80%155.31M | -56.49%200.94M | 1.39%135.3M | -28.49%461.82M |
| Profit attributable to shareholders | 14.02%150.03M | -43.55%198.01M | -40.11%131.59M | 38.84%350.77M | 41.47%219.72M | 25.73%252.64M | 14.80%155.31M | -56.49%200.94M | 1.39%135.3M | -28.49%461.82M |
| Basic earnings per share | 16.47%0.389 | -43.37%0.504 | -40.04%0.334 | 38.85%0.89 | 41.37%0.557 | 25.69%0.641 | 14.87%0.394 | -56.48%0.51 | 1.18%0.343 | -28.05%1.172 |
| Diluted earnings per share | 16.47%0.389 | -43.37%0.504 | -40.04%0.334 | 38.85%0.89 | 41.37%0.557 | 25.69%0.641 | 14.87%0.394 | -56.48%0.51 | 1.18%0.343 | -28.05%1.172 |
| Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
| Auditor | -- | PwC accounting firm | -- | PwC accounting firm | -- | KPMG | -- | KPMG | -- | KPMG |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.